News, Links and Commentary
Tuesday, October 11, 2005
European Trial of Photrex for Wet MD
Miravant Medical Technologies have announced a confirmatory Phase III clinical trial of their light-activated drug, Photrex (TM), also known as SnET2 and rostaporfin. Around 650 patients at 50 sites in the UK and Central and Eastern Europe, who have either the classic or occult forms of wet macular degeneration, will receive the treatment. The trial will be reviewed by the US Food and Drug Administration. More information is available in Miravant's media release, 'Miravant's Confirmatory Phase III Clinical Trial of PHOTREX(TM) in Patients with Age-Related Macular Degeneration Is Underway' (10 October 2005, at Genetic Engineering News).
Comments:
Post a Comment
